JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Madrigal Pharmaceuticals Inc

Cerrado

SectorSalud

424.5 1.94

Resumen

Variación precio

24h

Actual

Mínimo

413

Máximo

424.77

Métricas clave

By Trading Economics

Ingresos

31M

-42M

Ventas

76M

213M

BPA

-1.9

Margen de beneficio

-19.869

Empleados

528

EBITDA

31M

-39M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+21.75% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

2.9B

9.8B

Apertura anterior

422.56

Cierre anterior

424.5

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

163 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Madrigal Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

23 oct 2025, 20:49 UTC

Ganancias

Correction to Thermo Fisher Article on Oct. 22

23 oct 2025, 23:51 UTC

Charlas de Mercado

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 oct 2025, 23:49 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 oct 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 oct 2025, 23:37 UTC

Charlas de Mercado

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 oct 2025, 22:58 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

23 oct 2025, 22:57 UTC

Charlas de Mercado

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 oct 2025, 22:49 UTC

Adquisiciones, fusiones, absorciones

How Trump Sparked a New Era of State Capitalism -2-

23 oct 2025, 22:49 UTC

Adquisiciones, fusiones, absorciones

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 oct 2025, 22:17 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 oct 2025, 21:41 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 oct 2025, 21:05 UTC

Ganancias

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

23 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

23 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

23 oct 2025, 20:35 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 oct 2025, 20:28 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 oct 2025, 20:15 UTC

Charlas de Mercado
Ganancias

Global Commodities Roundup: Market Talk

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q Adj EPS $1.71

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q Sales $5.52B

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q EPS $1.67

23 oct 2025, 20:09 UTC

Ganancias

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 oct 2025, 20:07 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

23 oct 2025, 20:07 UTC

Charlas de Mercado
Ganancias

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 oct 2025, 20:07 UTC

Ganancias

Blackstone Looks to IPOs for Investment Exits -- Update

23 oct 2025, 20:05 UTC

Ganancias

Intel 3Q Gross Margin 38.2% >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 oct 2025, 20:04 UTC

Ganancias

Intel: 4Q Guidance Excludes Altera >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel Sees 4Q Adj EPS 8c >INTC

Comparación entre iguales

Cambio de precio

Madrigal Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

21.75% repunte

Estimación a 12 meses

Media 506.43 USD  21.75%

Máximo 590 USD

Mínimo 266 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Madrigal Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

16 ratings

14

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

263.2 / 277.1Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

163 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat